Short Interest in Caring Brands, Inc. (NASDAQ:CABR) Declines By 48.5%

Caring Brands, Inc. (NASDAQ:CABR) was the recipient of a significant decline in short interest during the month of July. As of July 15th, there was short interest totaling 36,455 shares, a decline of 48.5% from the June 30th total of 70,819 shares. Approximately 0.5% of the shares of the company are sold short. Based on an average daily trading volume, of 85,145 shares, the days-to-cover ratio is presently 0.4 days.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Caring Brands from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Caring Brands has a consensus rating of “Sell”.

Institutional Trading of Caring Brands

An institutional investor recently bought a new position in Caring Brands stock. Jane Street Group LLC bought a new position in Caring Brands, Inc. (NASDAQ:CABR) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned about 0.25% of Caring Brands at the end of the most recent reporting period.

Caring Brands Stock Up 1.3%

Shares of CABR stock traded up $0.02 during mid-day trading on Thursday, reaching $1.58. 2,097 shares of the stock traded hands, compared to its average volume of 107,102. Caring Brands has a 1-year low of $0.71 and a 1-year high of $5.35. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.62 and a current ratio of 5.66. The stock has a market capitalization of $14.36 million and a P/E ratio of -2.47. The business has a fifty day moving average price of $1.27.

Caring Brands (NASDAQ:CABR) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.27) EPS for the quarter.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.